bioAffinity Technologies, Inc.(BIAF)Earnings, Financials & Key RatiosbioAffinity Technologies, Inc. (BIAF) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's current ratio has deteriorated to 1.36, and the persistent operating margin of -2.7% in 2026Q1 indicates significant risk of continued capital dilution.
bioAffinity Technologies, Inc. (BIAF) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
bioAffinity Technologies, Inc. (BIAF) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.81vs $2.40+66.3% | $1Mvs $1M-8.9% |
| Q2 2026 | Mar 13, 2026 | $1.11vs $2.70+58.9% | $2Mvs $2M+2.5% |
| Q4 2025 | Nov 14, 2025 | $2.70vs $2.70+0.0% | $1Mvs $1M+2.5% |
| Q3 2025 | Aug 14, 2025 | $3.90vs $2.70-44.4% | $1Mvs $1M-10.0% |
Recent stock market news and headlines for bioAffinity Technologies, Inc. (BIAF)
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technology reports continued acceleration in commercial sales for its CyPath® Lung diagnostic with more than 200% growth year-over-year.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports on preclinical findings that demonstrate siRNA therapy kills skin cancer cells while sparing healthy cells.
JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $3.2 million offering.
JERSEY CITY, N.J., June 17, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, priced a Public Offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.
Key metrics vs top competitors for bioAffinity Technologies, Inc. (BIAF)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.83 | $3.76M | -0.10 | -34.18% | -241.96% | -301.83% | — | |
| $1.53 | $64.62M | -1.15 | 8.01% | -60.09% | -92.94% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $28.31 | $1.46B | -70.78 | 13.79% | -1.98% | -2.61% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $150.65 | $8.82B | -45.93 | 32.33% | -34.34% | -26.46% | — |
bioAffinity Technologies, Inc. (BIAF) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
bioAffinity Technologies, Inc. (BIAF) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 27, 2026·SEC
May 12, 2026·SEC
May 8, 2026·SEC
Mar 16, 2026·SEC
Get notified when BIAF posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
bioAffinity Technologies, Inc. (BIAF) stock FAQ — growth, dividends, profitability & financials explained
bioAffinity Technologies, Inc. (BIAF) reported $5.7M in revenue for fiscal year 2025.
bioAffinity Technologies, Inc. (BIAF) saw revenue decline by 34.2% over the past year.
bioAffinity Technologies, Inc. (BIAF) reported a net loss of $15.9M for fiscal year 2025.
bioAffinity Technologies, Inc. (BIAF) has a return on equity (ROE) of -301.8%. Negative ROE indicates the company is unprofitable.
bioAffinity Technologies, Inc. (BIAF) had negative free cash flow of $10.9M in fiscal year 2025, likely due to heavy capital investments.
